Applications are now being accepted for IDSA Fellowship. FIDSA honors members who have achieved professional excellence and provided significant service to the profession in clinical practice, research, administration, or education

Help us celebrate the field of ID by nominating dedicated clinicians, promising young researchers, outstanding mentors, and those who have had a lifetime of impact on the field for an IDSA Society Award.

Tune into the IDSA Facebook page on March 12 at  1 p.m. ET as we premiere our discussion with IDSA Board member Helen Boucher, MD, FIDSA, on antibiotic resistance and the urgent need for new antibiotics.

With evidence that the number of measles cases and outbreaks this year is already well on track to exceed last year’s numbers, the Senate Committee on Health, Education, Labor and Pensions held a hearing on March 5 drawing urgent attention to a central tenet of public health: vaccines save lives.

Please take two minutes to ask your members of Congress to support robust funding in the FY2020 budget to address infectious diseases and HIV. 

UnitedHealthcare announced last month that it would once again implement its “soft rejection” policy effective March 1 with modifications based on input from HIVMA and other provider and public health organizations.

IDSA and HIVMA are hosting The Big IDea: Infectious Diseases/HIV Education & Advocacy Day -- our first large scale day of action on Tuesday, Oct. 1 in Washington, DC. Interested in joining us? Sign up here.

IDSA needs your help reaching new members through two initiatives launching this spring -- The Digital Strategy Advisory Group and the Membership Ambassador Program. 

When it comes to vaccinations, parents trust the expertise of their doctor more than anyone else. CDC is asking for your help to ensure that all patients are up to date on MMR vaccine.

Infectious Disease News spoke with IDSA spokesperson Matthew Zahn, MD, FIDSA to get his perspective on findings from a recent study published in IDSA’s Clinical Infectious Diseases which reports that “early treatment with oseltamivir was associated with a 30% lower mortality rate compared with later treatment in patients with influenza A(H3N2) during eight recent influenza seasons in Greece.” This is just one of the several news pieces that IDSA and our member spokespersons contributed to. Read others here.